Nephros News (AMEX:NEP)

Latest Nephros News Headlines
DateTimeSource
Headline
05/15/20083:48PMPRNUSNephros Reports 2008 First Quarter Financial Results
NEW YORK, May 15 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) announced today financial results for the three month period ended March 31, 2008. Recent Highlights -- Increased product revenues by 31% to $387,000. -- Completed enrollment in the pivotal U.S. trial for the OLpur(TM) H2H(TM) Hemodiafiltration... More...>>
05/13/20084:23PMPRNUSNephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
Company Management to discuss the benefits of Hemodiafiltration therapy and Quality of Life for End-Stage Renal Disease Patients NEW YORK, May 13 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), a medical device company developing and marketing products designed to improve the quality of life for the End-Stage Renal... More...>>
04/29/20087:09PMPRNUSNephros Appoints Gerald J. Kochanski as Chief Financial Officer
NEW YORK, April 29 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) today announced that, effective April 28, 2008, Gerald J. Kochanski has been appointed Chief Financial Officer. Mr. Kochanski joins the company from Lordi Consulting LLC, where he has served as Director since 2007. "Jerry has a proven track record... More...>>
04/21/20088:30AMPRNUSNephros Strengthens Commercialization Team with Addition of Marketing Executive
NEW YORK, April 21 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), a medical device company specializing in the treatment of end-stage renal disease, today announced that it has named Joleen C. Turner to be Vice President of Marketing and Business Development, effective today. In this role, Ms. Turner, an experienced... More...>>
12/06/20068:00AMPRNUSItalian Clinical Study Demonstrates Nephros' Mid-Dilution HDF Therapy As Optimal Treatment for Patients with Limited Vascular Ac
Dr. Renaux Presented Clinical Study Results at American Society of Nephrology's Renal Week 2006 NEW YORK, Dec. 6 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), announced today the results of a clinical study conducted at the Maggiore Hospital in Lodi, Italy, by Jean Louis Renaux, PhD, Director of Scientific Affairs... More...>>
11/20/20068:00AMPRNUSAmerican Stock Exchange Will Continue Nephros's Listing
NEW YORK, Nov. 20 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) today announced that the staff of the American Stock Exchange (AMEX) has reviewed the Company's plan of compliance to meet the AMEX's continued listing standards and will continue the Company's listing while the Company seeks to regain compliance with... More...>>
11/15/20068:00AMPRNUSNephros Reports Third Quarter 2006 Financial Results
NEW YORK, Nov. 15 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) announced today financial results for the three months and nine months ended September 30, 2006. For the quarter ended September 30, 2006, Nephros reported net revenue of $164,699, attributable to sales of its OLpur(TM) MDHDF products in Europe, compared... More...>>
10/23/20068:00AMPRNUSMulti-Center Study Concludes Nephros Mid-Dilution Hemodiafiltration Therapy Achieves Higher Clearance of Low Molecular Weight Pr
Study Abstract Selected by Peer-Review Experts for Presentation at American Society of Nephrology (ASN) Congress NEW YORK, Oct. 23 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), announced today that the results of a randomized, multi-site scientific study indicate that the Company's Mid-Dilution Hemodiafiltration... More...>>
10/05/20068:00AMPRNUSNephros Announces Positive Results of Clinical Study for Olpur MD190 Mid-Dilution Hemodiafiltration Filter
Study Findings to be Presented at October Nephrology Congress in Madrid NEW YORK, Oct. 5 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), announced the positive results of a recent pilot clinical study confirming that the Company's proprietary end stage renal disease ("ESRD") therapy, Mid- Dilution Hemodiafiltration... More...>>
10/04/20068:00AMPRNUSNephros Selected for Development of Dual Stage Ultra Reliable Portable Personal Water Filtration by U.S. Marine Corps ATD
$1 Million Department of Defense Appropriation Approved NEW YORK, Oct. 4 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), announced today that it will be working with the United States Marine Corps Warfighting Laboratory in Quantico, Va. to develop a portable personal water purification system following the approval... More...>>
08/22/20065:27PMPRNUSNephros Announces Restatement of Financial Statements
NEW YORK, Aug. 22 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), today announced that the management, Board of Directors and Audit Committee of the Board of Directors of the Company concluded that the previously reported financial statements covering the period ended March 31, 2006 should no longer be relied upon... More...>>
08/17/20064:30PMPRNUSNephros Receives Extension to Submit AMEX Plan of Compliance
NEW YORK, Aug. 17 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) today announced that the American Stock Exchange (AMEX) has granted the Company a one week extension, until August 24, 2006, to submit a plan of compliance advising the AMEX of the action the Company has taken, or will take, that would bring it into... More...>>
08/04/20064:30PMPRNUSNephros Selects Director William Fox to Serve as Executive Chairman
NEW YORK, Aug. 4 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), announced today the appointment of William J. Fox, CPA, as Executive Chairman of the Board. Mr. Fox has served as a Director since the Company's initial public offering in September 2004. Mr. Fox will replace Dr. Eric Rose, Professor and Chair of... More...>>
07/21/20064:15PMPRNUSNephros Receives Non-compliance Notification from AMEX
NEW YORK, July 21 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) today announced that the Company has received notice from the American Stock Exchange (AMEX) that AMEX has determined that the Company is not in compliance with certain conditions of the continued listing standards of Section 1003 of the AMEX Company... More...>>


LSE and PLUS quotes are live. NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions :: Contact Us :: Request an Exchange :: Affiliate Scheme
Copyright1999-2008 ADVFN PLC. Copyright and limited reproduction :: Privacy Policy :: Investment Warning :: Advertise with us :: Data accreditations :: Investor Relations :: Press office :: Jobs
ADDITIONAL SERVICES AVAILABLE FROM ADVFN
Upgrade - Click here for more information on ADVFN premium services Money Words - ADVFN Financial Glossary Investor Training ADVFN Financial Bookshop Online Training Academy
41 site:2us amex nep080517 04:37 Stock Message Boards ( 2001 | 2002 | 2003 | 2004 | 2005 | 2005 | 2007 )